ITGAX and neoplasm: In tumor-bearing mice or in CD11c-β-catenin<sup>active</sup> mice, which model β-catenin-driven DC dysfunction, Tim-3-targeted vaccination restored cross-priming and counteracted tumor- and DC-mediated immunosuppression.